Abstract:e24276 Background: Hepatocellular carcinoma (HCC), the most common hepatic malignancy, is the second leading cause of cancer-related death worldwide. China accounts for more than 50% of new HCC cases and deaths in the world. The genomic profiles of HCC in Chinese patients had not been thoroughly elucidated to facilitate diagnosis and treatment. Methods: FFPE tumor and matched blood samples of 181 Chinese HCC patients, including 152 males (median age of 54) and 29 females (median age of 52), were collected for next-generation sequencing-based 450 genes panel assay. Genomic alterations (including single base substitutions, short and long insertions/deletions, copy number variations, and gene rearrangement in selected genes) and tumor mutational burden were assessed. In addition, the expression of tumor cell PDL1 was also evaluated by FDA-cleared DAKO 22c3 antibody. Results: The most frequently mutated genes in 181 Chinese HCC were TP53 (59.7%), TERT (34.3%), CTNNB1 (21.5%), AXIN1 (12.2%), RB1 (11.0%), STK24 (11.0%), ARID1A (9.9%), CCND1 (7.7%), TSC2 (6.6%) and FGF19 (6.6%). The mutation rates of TERT (p = 0.027) and RB1 (p = 0.016) were significantly higher in patients (pts) with TMB greater than the cohort medium of 7.2 muts/Mb. In addition, loss of function mutation of PBRM1 was found in 2.8% of the pts. About 7% of the patients had TMB value higher than 20 muts/Mb, compared to 1-2% in Western HCC pts, and 31% higher than 10 muts/Mb. Seventy-four patients (median age 54 years; median TMB 6.8 muts/Mb) had tumorous PDL1 expressions assessed by IHC assay. Thirty-six percent of patients were positive of PDL1 (tumor portion score TPS greater than 1%). Only three pts possessed both high TMB and high PDL1 expression (TPS > 50). No correlation was observed between the expression of PDL1 and TMB (r = 0.1). Conclusions: This is the first genomic profiling study of Chinese HCC pts along with TMB and PDL1 expression results. With less actionable gene alterations but more often high TMB and PDL1 expression than their Western counterparts, Chinese HCC pts could potentially benefit more from immune check point inhibitor-based therapies. However, no correlation was observed between the expressions of PDL1 and TMB values.

Cmar_a_192845 3053..3060

Ott_a_231052 11033..11044

Cmar_a_286796 537..546

Plenary Paper

Ott_a_203342 8355..8365

Cmar_a_197337 6343..6351

Characterization of Genomic Alterations, Tumor Mutational Burden and PDL1 Expression in 181 Chinese Hepatocellular Carcinomas.

Cmar_a_197052 3993..4003

Cmar_a_346406 775..820

Cmar_a_338788 237..247

Cmar_a_195130 4855..4870

Cmar_a_240869 1621..1630

Cmar_a_197544 6365..6376

Cmar_a_287993 1887..1896

Cmar_a_234271 1387..1396

Cmar_a_208631 6185..6199

Cmar_a_236618 4883..4888

Ott_a_227644 389..399

Cmar_a_236696 2047..2055

Cmar_a_201793 5375..5391

Cmar_a_214020 9121..9131